xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT05996835</url>
    </required_header>
    <id_info>
      <org_study_id>CTIN816B12202</org_study_id>
      <nct_id>NCT05996835</nct_id>
    </id_info>
    <brief_title>Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (SA-AKI)</brief_title>
    <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled, Four-arm, Parallel-group, Dose-finding Phase 2b Study to Investigate the Safety and Efficacy of TIN816 Via a Single Intravenous Infusion in the Treatment of Participants With Sepsis-associated Acute Kidney Injury (SA-AKI)</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Novartis Pharmaceuticals</agency>
        <agency_class>Industry</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>Novartis</source>
    <oversight_info>
      <has_dmc>Yes</has_dmc>
      <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        The purpose of this Ph2b study is to characterize the dose-response relationship and to&#xD;
        evaluate the safety and efficacy of three different single doses of TIN816 in hospitalized&#xD;
        adult participants in an intensive care setting with a diagnosis of sepsis-associated acute&#xD;
        kidney injury (SA-AKI).&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        This is a multicenter, randomized, double-blind, placebo-controlled, four-arm,&#xD;
        parallel-group, dose-finding phase 2b study. The study will enroll hospitalized adult&#xD;
        participants with a diagnosis of sepsis and acute kidney injury (AKI). The study consists of&#xD;
        a screening period (24-48 hours), a treatment period (Day 1), and post-treatment period (Day&#xD;
        2 to 90). Screening will take place during hospitalization in ICU (or intermediate care&#xD;
        unit/HDU) where potential participants will undergo screening to assess the presence of&#xD;
        sepsis and AKI. At Treatment Day 1, participants who meet eligibility criteria at screening&#xD;
        and baseline will be randomized in a 3:1:1:3 ratio to receive a one-time treatment of TIN816&#xD;
        or placebo by intravenous infusion in a participant and investigator-blinded fashion.&#xD;
        Treatment Day 1 is followed by a 90-day post-treatment period for safety and efficacy&#xD;
        assessments. An interim analysis (IA) is planned when approximately 120 participants complete&#xD;
        Day 30 visit. A final analysis will be performed after all participants have completed Day&#xD;
        90.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">December 6, 2023</start_date>
    <completion_date type="Anticipated">February 16, 2026</completion_date>
    <primary_completion_date type="Anticipated">November 28, 2025</primary_completion_date>
    <phase>Phase 2</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>Randomized</allocation>
      <intervention_model>Parallel Assignment</intervention_model>
      <primary_purpose>Treatment</primary_purpose>
      <masking>Triple (Participant, Care Provider, Investigator)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>Average of area under the time-corrected creatinine clearance curve (AUC1-8)</measure>
      <time_frame>Day 1 to Day 8</time_frame>
      <description>The weighted average of area under the time-corrected endogenous creatinine clearance curve.&#xD;
  Urine volume, urinary creatinine, and the serum creatinine measurements will be used for calculation. Day 1-8 measurements will be included.</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Percentage of participants with major adverse kidney events (MAKE)</measure>
      <time_frame>Day 1 to Day 90</time_frame>
      <description>A binary composite endpoint of major adverse kidney events (MAKE) including death, use of Renal Replacement Therapy (RRT) and ≥25% reduction in estimated Glomular Filtration Rate (eGFR) at Day 90.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Area under the time-corrected endogenous serum creatinine curve for Day 1 to Day 14 and Day 1 to Day 30.</measure>
      <time_frame>Day 1 to Day 14 and Day 1 to Day 30</time_frame>
      <description>The weighted average of area under the time-corrected endogenous serum creatinine curve from Day 1 to Day 14 and Day 1 to Day 30.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Area under the time-corrected endogenous serum cystatin C curve for Day 1 to Day 14 and Day 1 to Day 30</measure>
      <time_frame>Day 1 to Day 14 and Day 1 to Day 30</time_frame>
      <description>The weighted average of area under the time-corrected endogenous serum cystatin-C curve from Day 1 to Day 14 and Day 1 to Day 30.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Area under the time-corrected creatinine clearance curve (AUC5-14)</measure>
      <time_frame>Day 5 to Day 14</time_frame>
      <description>The weighted average of area under the time-corrected endogenous creatinine clearance curve.&#xD;
  Urine volume, urinary creatinine, and the serum creatinine measurements will be used for calculation. Day 5-14 measurements will be included.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Percentage of participants who had renal replacement therapy (RRT) from Day 1 to Day 90</measure>
      <time_frame>Day 1 to Day 90</time_frame>
      <description>Use of RRT at any time during the treatment period will be reported.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Percentage of participants with RRT dependency at Day 90</measure>
      <time_frame>Day 90</time_frame>
      <description>Use of RRT dependency at Day 90 will be reported</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Number of days participants alive and free of RRT from Day 1 to Day 90</measure>
      <time_frame>Day 1 to Day 90</time_frame>
      <description>Participants who are alive and free of RRT, defined as any participant receiving any form of RRT, will be reported.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change in Kidney disease improving global outcomes (KDIGO) score from Baseline to Day 14</measure>
      <time_frame>14 Days</time_frame>
      <description>The KDIGO classification system stages AKI into three levels based on serum creatinine elevation in parallel with degree and duration of oliguria. Participants are classified based on the worst finding (either serum creatinine or oliguria). The stages range from 1-3, with higher scores indicating the most severe stage of AKI.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Percentage of participants with ≥25% reduction in eGFR at Day 90</measure>
      <time_frame>90 Days</time_frame>
      <description>Percentage of participants with ≥ 25% reduction from baseline to Day 90.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Mean change of sequential organ failure score (SOFA) from baseline to Day 30</measure>
      <time_frame>30 Days</time_frame>
      <description>The SOFA score was developed to assess the acute morbidity of critical illness at a population level. The score is routinely calculated on admission to ICU and at each 24-hour period that follows. It is composed of six criteria which reflect the function of a specific organ system (respiratory, cardiovascular, renal, neurological, hepatic and hematological) and allocates a score of 0-4.&#xD;
  Scores ranges from 0-24, with higher scores indicating greater dysfunction.</description>
    </secondary_outcome>
    <number_of_arms>4</number_of_arms>
    <enrollment type="Anticipated">320</enrollment>
    <condition>Acute Kidney Injury Due to Sepsis</condition>
    <arm_group>
      <arm_group_label>TIN816 Dose A</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Administered as a one-time intravenous dose</description>
    </arm_group>
    <arm_group>
      <arm_group_label>TIN816 Dose B</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Administered as a one-time intravenous dose</description>
    </arm_group>
    <arm_group>
      <arm_group_label>TIN816 Dose C</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Administered as a one-time intravenous dose</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Placebo</arm_group_label>
      <arm_group_type>Placebo Comparator</arm_group_type>
      <description>0.9% sterile saline administered as a one- time intravenous dose</description>
    </arm_group>
    <intervention>
      <intervention_type>Biological</intervention_type>
      <intervention_name>TIN816 70 mg lyophilisate powder</intervention_name>
      <description>Immunotherapy Recombinant human CD39 enzyme</description>
      <arm_group_label>TIN816 Dose A</arm_group_label>
      <arm_group_label>TIN816 Dose B</arm_group_label>
      <arm_group_label>TIN816 Dose C</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Other</intervention_type>
      <intervention_name>Placebo</intervention_name>
      <description>0.9% sterile saline solution</description>
      <arm_group_label>Placebo</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            1. Signed informed consent must be obtained prior to participation in the study.&#xD;
  &#xD;
            2. ≥ 18 to ≤ 85 years of age&#xD;
  &#xD;
            3. Admitted to ICU or intermediate care unit/ high dependency care unit (HDU)&#xD;
  &#xD;
            4. Diagnosis of sepsis according to criteria defined by The Third International Consensus&#xD;
               Definitions for Sepsis and Septic Shock (Sepsis-3) based on:&#xD;
  &#xD;
                 -  Suspected or confirmed infection AND&#xD;
  &#xD;
                 -  Acute increase of SOFA score of 2 or more (excluding renal component). The&#xD;
                    baseline SOFA score should be assumed to be zero unless the participant is known&#xD;
                    to have pre-existing (acute or chronic) organ dysfunction before the onset of&#xD;
                    infection&#xD;
  &#xD;
            5. Diagnosis of AKI Stage 1 or greater per the following criterion at randomization:&#xD;
  &#xD;
          An absolute increase in serum or plasma creatinine by ≥ 0.3 mg/dL (≥ 26.5 µmol/L) within 48&#xD;
          hours or presumed to have occurred in the previous 48 hours as compared to the reference&#xD;
          serum creatinine.&#xD;
  &#xD;
            -  For participants with hospital-acquired AKI, a stable serum creatinine obtained in the&#xD;
               hospital prior to AKI diagnosis should be used as the reference serum creatinine.&#xD;
  &#xD;
            -  For participants presenting from community, the reference serum creatinine should be&#xD;
               estimated using the following order of preference:&#xD;
  &#xD;
                 1. The most recent value within 3 months of the hospital admission. If not&#xD;
                    available:&#xD;
  &#xD;
                 2. The most recent value between 3 and 12 months prior to hospital admission. If not&#xD;
                    available:&#xD;
  &#xD;
                 3. At hospital admission&#xD;
  &#xD;
          Exclusion criteria&#xD;
  &#xD;
            1. Not expected to survive for 24 hours&#xD;
  &#xD;
            2. Not expected to survive for 30 days due to medical conditions other than SA-AKI&#xD;
  &#xD;
            3. History of CKD with a documented estimated GFR &lt;45 mL/min prior to admission to&#xD;
               hospital&#xD;
  &#xD;
            4. eGFR &lt;45mL/min at admission without any other reference serum eGFR within last&#xD;
               12-months&#xD;
  &#xD;
            5. Receiving RRT or a decision has been made to initiate RRT within 24 hours after&#xD;
               randomization&#xD;
  &#xD;
            6. Weight is less than 40 kg or more than 125 kg.&#xD;
  &#xD;
            7. Limitations to the use of mechanical ventilation, RRT or vasopressors/inotropes (N.B.&#xD;
               limitations on Cardiopulmonary resuscitation (CPR)e.g., do-not-resuscitate orders are&#xD;
               not an exclusion criterion unless associated with likely poor outcome in next 24&#xD;
               hours)&#xD;
  &#xD;
            8. Sepsis diagnosis according to sepsis inclusion criteria for a period longer than 72&#xD;
               hours prior to ICU admission&#xD;
  &#xD;
            9. AKI diagnosis according to AKI inclusion criteria over 48 hours after admission to ICU&#xD;
  &#xD;
           10. Inability to administer study drug within 24 hours of diagnosis of AKI according to&#xD;
               AKI inclusion criteria&#xD;
  &#xD;
           11. Presence of AKI, in the Investigator's opinion, as suggested by clinical&#xD;
               manifestation, e.g., prolonged oliguria or severe renal dysfunction on admission&#xD;
               without a history of CKD, for a period longer than 24 hours prior to study drug&#xD;
               administration&#xD;
  &#xD;
           12. Evidence of recovery from AKI based on the investigator's clinical judgement prior to&#xD;
               randomization&#xD;
  &#xD;
           13. AKI is most likely attributable to other causes than sepsis, such as nephrotoxic drugs&#xD;
               (Non-steroidal anti-inflammatory drugs (NSAIDs), contrast, aminoglycosides, etc.) or&#xD;
               renal perfusion-related (acute abdominal aortic aneurysm, dissection, renal artery&#xD;
               stenosis), urinary obstruction&#xD;
  &#xD;
           14. Documented (biopsy proven) or suspected history of acute or sub-acute kidney diseases&#xD;
               such as rapidly progressive glomerular nephritis (RPGN) and acute interstitial&#xD;
               nephritis (AIN)&#xD;
  &#xD;
           15. Patients who are post-nephrectomy&#xD;
  &#xD;
           16. Patients who are thrombocytopenic at screening (platelet count &lt;50,000 per microliter)&#xD;
               or other high risk for bleeding in the opinion of the investigator&#xD;
  &#xD;
           17. Immunosuppressed patients&#xD;
  &#xD;
                 -  History of immunodeficiency diseases&#xD;
  &#xD;
                 -  Receiving immunosuppressant treatment or on chronic high doses (high-dose therapy&#xD;
                    exceeding 2 weeks of treatment) of steroids equivalent to prednisone/prednisolone&#xD;
                    0.5 mg/kg/day, including solid organ transplant patients. Patients with septic&#xD;
                    shock treated with corticosteroids (as per the Surviving Sepsis Guidelines) can&#xD;
                    be included. See Appendix Section 10.6 Immunosuppresant drugs, (Table 10 5&#xD;
                    Immunosuppressant drug exclusions)&#xD;
  &#xD;
           18. Known active hepatitis B or C infection, or positive Hepatitis B Virus (HBV) or&#xD;
               Hepatitis C Virus (HCV) serology or patients with advanced chronic liver disease,&#xD;
               confirmed by a Child-Pugh score of 10-15 (Class C)&#xD;
  &#xD;
           19. Acute pancreatitis with no established source of infection&#xD;
  &#xD;
           20. Active hematological malignancy (previous hematological malignancies that are not&#xD;
               actively treated are allowable)&#xD;
  &#xD;
           21. Burns requiring ICU treatment&#xD;
  &#xD;
           22. Sepsis attributed to confirmed COVID-19&#xD;
  &#xD;
           23. Use of other investigational drugs within 5 half-lives of enrollment, within 30 days&#xD;
               (e.g., small molecules) or until the expected pharmacodynamic effect has returned to&#xD;
               baseline (e.g., biologics), whichever is longer; or longer if required by local&#xD;
               regulations&#xD;
  &#xD;
           24. History of hypersensitivity to the study treatment or its excipients or to drugs of&#xD;
               similar chemical classes&#xD;
  &#xD;
           25. Any medical conditions that could significantly increase risk of participants' safety&#xD;
               by participating in this study according to investigator's judgement&#xD;
  &#xD;
           26. Women with a positive pregnancy test, pregnancy or breast feeding&#xD;
  &#xD;
           27. Women of childbearing potential, unless they are using highly effective methods of&#xD;
               contraception for the entire duration of the trial.&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>85 Years</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Novartis Pharmaceuticals</last_name>
      <role>Study Director</role>
      <affiliation>Novartis Pharmaceuticals</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Novartis Pharmaceuticals</last_name>
      <phone>1-888-669-6682</phone>
      <email>novartis.email@novartis.com</email>
    </overall_contact>
    <overall_contact_backup>
      <last_name>Novartis Pharmaceuticals</last_name>
      <phone>+41613241111</phone>
    </overall_contact_backup>
    <verification_date>September 2023</verification_date>
    <study_first_submitted>August 10, 2023</study_first_submitted>
    <study_first_submitted_qc>August 10, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 18, 2023</study_first_posted>
    <last_update_submitted>September 4, 2023</last_update_submitted>
    <last_update_submitted_qc>September 4, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">September 7, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <keyword>Sepsis</keyword>
    <keyword>acute kidney injury</keyword>
    <keyword>anti-inflammatory</keyword>
    <keyword>immunosuppression</keyword>
    <keyword>intensive care unit</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Sepsis</mesh_term>
      <mesh_term>Toxemia</mesh_term>
      <mesh_term>Acute Kidney Injury</mesh_term>
      <mesh_term>Wounds and Injuries</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>Yes</sharing_ipd>
      <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
  This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT05996835
  org study id: CTIN816B12202
  nct id: NCT05996835
  lead sponsor: 
  has dmc: Yes
  is fda regulated drug: Yes
  is fda regulated device: No
  The purpose of this Ph2b study is to characterize the dose-response relationship and to
        evaluate the safety and efficacy of three different single doses of TIN816 in hospitalized
        adult participants in an intensive care setting with a diagnosis of sepsis-associated acute
        kidney injury (SA-AKI).
  This is a multicenter, randomized, double-blind, placebo-controlled, four-arm,
        parallel-group, dose-finding phase 2b study. The study will enroll hospitalized adult
        participants with a diagnosis of sepsis and acute kidney injury (AKI). The study consists of
        a screening period (24-48 hours), a treatment period (Day 1), and post-treatment period (Day
        2 to 90). Screening will take place during hospitalization in ICU (or intermediate care
        unit/HDU) where potential participants will undergo screening to assess the presence of
        sepsis and AKI. At Treatment Day 1, participants who meet eligibility criteria at screening
        and baseline will be randomized in a 3:1:1:3 ratio to receive a one-time treatment of TIN816
        or placebo by intravenous infusion in a participant and investigator-blinded fashion.
        Treatment Day 1 is followed by a 90-day post-treatment period for safety and efficacy
        assessments. An interim analysis (IA) is planned when approximately 120 participants complete
        Day 30 visit. A final analysis will be performed after all participants have completed Day
        90.
  allocation: Randomized
  intervention model: Parallel Assignment
  primary purpose: Treatment
  masking: Triple (Participant, Care Provider, Investigator)
  measure: Average of area under the time-corrected creatinine clearance curve (AUC1-8)
  time frame: Day 1 to Day 8
  description: The weighted average of area under the time-corrected endogenous creatinine clearance curve.
  Urine volume, urinary creatinine, and the serum creatinine measurements will be used for calculation. Day 1-8 measurements will be included.
  measure: Percentage of participants with major adverse kidney events (MAKE)
  time frame: Day 1 to Day 90
  description: A binary composite endpoint of major adverse kidney events (MAKE) including death, use of Renal Replacement Therapy (RRT) and ≥25% reduction in estimated Glomular Filtration Rate (eGFR) at Day 90.
  measure: Area under the time-corrected endogenous serum creatinine curve for Day 1 to Day 14 and Day 1 to Day 30.
  time frame: Day 1 to Day 14 and Day 1 to Day 30
  description: The weighted average of area under the time-corrected endogenous serum creatinine curve from Day 1 to Day 14 and Day 1 to Day 30.
  measure: Area under the time-corrected endogenous serum cystatin C curve for Day 1 to Day 14 and Day 1 to Day 30
  time frame: Day 1 to Day 14 and Day 1 to Day 30
  description: The weighted average of area under the time-corrected endogenous serum cystatin-C curve from Day 1 to Day 14 and Day 1 to Day 30.
  measure: Area under the time-corrected creatinine clearance curve (AUC5-14)
  time frame: Day 5 to Day 14
  description: The weighted average of area under the time-corrected endogenous creatinine clearance curve.
  Urine volume, urinary creatinine, and the serum creatinine measurements will be used for calculation. Day 5-14 measurements will be included.
  measure: Percentage of participants who had renal replacement therapy (RRT) from Day 1 to Day 90
  time frame: Day 1 to Day 90
  description: Use of RRT at any time during the treatment period will be reported.
  measure: Percentage of participants with RRT dependency at Day 90
  time frame: Day 90
  description: Use of RRT dependency at Day 90 will be reported
  measure: Number of days participants alive and free of RRT from Day 1 to Day 90
  time frame: Day 1 to Day 90
  description: Participants who are alive and free of RRT, defined as any participant receiving any form of RRT, will be reported.
  measure: Change in Kidney disease improving global outcomes (KDIGO) score from Baseline to Day 14
  time frame: 14 Days
  description: The KDIGO classification system stages AKI into three levels based on serum creatinine elevation in parallel with degree and duration of oliguria. Participants are classified based on the worst finding (either serum creatinine or oliguria). The stages range from 1-3, with higher scores indicating the most severe stage of AKI.
  measure: Percentage of participants with ≥25% reduction in eGFR at Day 90
  time frame: 90 Days
  description: Percentage of participants with ≥ 25% reduction from baseline to Day 90.
  measure: Mean change of sequential organ failure score (SOFA) from baseline to Day 30
  time frame: 30 Days
  description: The SOFA score was developed to assess the acute morbidity of critical illness at a population level. The score is routinely calculated on admission to ICU and at each 24-hour period that follows. It is composed of six criteria which reflect the function of a specific organ system (respiratory, cardiovascular, renal, neurological, hepatic and hematological) and allocates a score of 0-4.
  Scores ranges from 0-24, with higher scores indicating greater dysfunction.
  arm group label: TIN816 Dose A
  arm group type: Experimental
  description: Administered as a one-time intravenous dose
  arm group label: TIN816 Dose B
  arm group type: Experimental
  description: Administered as a one-time intravenous dose
  arm group label: TIN816 Dose C
  arm group type: Experimental
  description: Administered as a one-time intravenous dose
  arm group label: Placebo
  arm group type: Placebo Comparator
  description: 0.9% sterile saline administered as a one- time intravenous dose
  intervention type: Biological
  intervention name: TIN816 70 mg lyophilisate powder
  description: Immunotherapy Recombinant human CD39 enzyme
  arm group label: TIN816 Dose A
  arm group label: TIN816 Dose B
  arm group label: TIN816 Dose C
  intervention type: Other
  intervention name: Placebo
  description: 0.9% sterile saline solution
  arm group label: Placebo
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: 85 Years
  healthy volunteers: No
  last name: Novartis Pharmaceuticals
  role: Study Director
  affiliation: Novartis Pharmaceuticals
  last name: Novartis Pharmaceuticals
  phone: 1-888-669-6682
  email: novartis.email@novartis.com
  last name: Novartis Pharmaceuticals
  phone: +41613241111
  responsible party type: Sponsor
  mesh term: Sepsis
  mesh term: Toxemia
  mesh term: Acute Kidney Injury
  mesh term: Wounds and Injuries
  sharing ipd: Yes
  ipd description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
  This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com